Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England
Open Access
- 13 December 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet Regional Health - Europe
- Vol. 13, 100260
- https://doi.org/10.1016/j.lanepe.2021.100260
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationThe New England Journal of Medicine, 2021
- First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in ScotlandNature Medicine, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort studyBMJ, 2021
- Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)Vaccine, 2021
- Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)Research and Practice in Thrombosis and Haemostasis, 2021
- Viral Coagulopathy in Patients With COVID-19: Treatment and CareClinical and Applied Thrombosis/hemostasis, 2020
- Pitfalls of the healthy vaccinee effectThe Lancet, 2018